Daniel Arumí

517 total citations
40 papers, 413 citations indexed

About

Daniel Arumí is a scholar working on Urology, Rheumatology and Epidemiology. According to data from OpenAlex, Daniel Arumí has authored 40 papers receiving a total of 413 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Urology, 26 papers in Rheumatology and 12 papers in Epidemiology. Recurrent topics in Daniel Arumí's work include Urinary Bladder and Prostate Research (30 papers), Pelvic floor disorders treatments (26 papers) and Urinary Tract Infections Management (12 papers). Daniel Arumí is often cited by papers focused on Urinary Bladder and Prostate Research (30 papers), Pelvic floor disorders treatments (26 papers) and Urinary Tract Infections Management (12 papers). Daniel Arumí collaborates with scholars based in Spain, United States and United Kingdom. Daniel Arumí's co-authors include Javier Rejas, Salvador Arlandis, J.C. Angulo, Adrian Wagg, Matthias Oelke, Pablo Rebollo, David Castro‐Díaz, Felipe Villacampa, Miguel A. Ruíz and P. Miranda and has published in prestigious journals such as Journal of Clinical Oncology, Age and Ageing and British Journal of Urology.

In The Last Decade

Daniel Arumí

39 papers receiving 408 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel Arumí Spain 12 349 323 169 112 33 40 413
Alexander Gomelsky United States 7 448 1.3× 529 1.6× 201 1.2× 238 2.1× 14 0.4× 12 635
Karen Irvine‐Bird Canada 9 297 0.9× 207 0.6× 164 1.0× 44 0.4× 12 0.4× 10 400
Danny Lovatsis Canada 15 213 0.6× 483 1.5× 115 0.7× 366 3.3× 10 0.3× 43 572
David Collas United Kingdom 8 103 0.3× 120 0.4× 159 0.9× 29 0.3× 6 0.2× 16 260
Yik N. Lim Australia 20 326 0.9× 976 3.0× 170 1.0× 859 7.7× 2 0.1× 36 1.1k
Hege Hølmo Johannessen Norway 12 26 0.1× 200 0.6× 45 0.3× 183 1.6× 4 0.1× 23 309
Lisa A. Trusler United States 10 147 0.4× 37 0.1× 17 0.1× 115 1.0× 5 0.2× 15 359
Lauren N. Wood United States 8 78 0.2× 192 0.6× 60 0.4× 158 1.4× 13 281
Ayhan Karabulut Türkiye 10 118 0.3× 66 0.2× 6 0.0× 141 1.3× 2 0.1× 22 233
Marc E. A. Spaanderman Netherlands 9 35 0.1× 156 0.5× 81 0.5× 90 0.8× 3 0.1× 13 313

Countries citing papers authored by Daniel Arumí

Since Specialization
Citations

This map shows the geographic impact of Daniel Arumí's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Arumí with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Arumí more than expected).

Fields of papers citing papers by Daniel Arumí

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Arumí. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Arumí. The network helps show where Daniel Arumí may publish in the future.

Co-authorship network of co-authors of Daniel Arumí

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Arumí. A scholar is included among the top collaborators of Daniel Arumí based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Arumí. Daniel Arumí is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cosı́n-Sales, Juan, et al.. (2024). Oral anticoagulant treatment in atrial fibrillation: the AFIRMA real-world study using natural language processing and machine learning. Revista Clínica Española (English Edition). 224(7). 428–436. 2 indexed citations
2.
Jiménez, Rosa María Romero, et al.. (2024). Cost-Effectiveness Analysis of Abrocitinib Compared with Other Systemic Treatments for Severe Atopic Dermatitis in Spain. PharmacoEconomics - Open. 8(2). 291–302. 5 indexed citations
3.
Cosı́n-Sales, Juan, et al.. (2024). Safety and Effectiveness of Oral Anticoagulants in Atrial Fibrillation: Real-World Insights Using Natural Language Processing and Machine Learning. Journal of Clinical Medicine. 13(20). 6226–6226. 1 indexed citations
4.
5.
Formiga, Françesc, et al.. (2020). Why are antithrombotic drugs not prescribed to octogenarian patients with atrial fibrillation at risk of stroke?. Medicina de Familia SEMERGEN. 46(6). 392–399. 1 indexed citations
6.
Goldman, Howard B., Matthias Oelke, Steven A. Kaplan, et al.. (2018). Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?. International Urogynecology Journal. 30(2). 239–244. 6 indexed citations
7.
8.
Angulo, J.C., et al.. (2016). Impacto del número de episodios diarios de incontinencia de urgencia en los resultados descritos por el paciente con vejiga hiperactiva. Actas Urológicas Españolas. 40(3). 173–182. 8 indexed citations
9.
Schneider, Tim, et al.. (2014). An observational study of patient satisfaction with fesoterodine in the treatment of overactive bladder: effects of additional educational material. International Journal of Clinical Practice. 68(9). 1074–1080. 7 indexed citations
10.
Wyndaele, J J, et al.. (2014). Flexible dosing with fesoterodine 4 and 8 mg: a systematic review of data from clinical trials. International Journal of Clinical Practice. 68(7). 830–840. 9 indexed citations
11.
12.
Angulo, J.C., et al.. (2014). La severidad de la vejiga hiperactiva modifica la carga asistencial y la productividad laboral. Actas Urológicas Españolas. 38(4). 249–256. 8 indexed citations
13.
Wagg, Adrian, Amanda Darekar, Daniel Arumí, Vik Khullar, & Matthias Oelke. (2014). Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people >65 years of age: A post hoc analysis of data from the SOFIA study. Neurourology and Urodynamics. 34(5). 438–443. 9 indexed citations
14.
Miranda, P., et al.. (2013). Beneficio terapéutico tras cambiar tolterodina por otros nuevos antimuscarínicos. Actas Urológicas Españolas. 38(3). 156–163. 3 indexed citations
15.
Cardozo, L., Sender Herschorn, L. Grenabo, et al.. (2013). 740 A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response to tolterodine extended release: Results from the AFTER study. European Urology Supplements. 12(1). e740–e741. 2 indexed citations
16.
Villacampa, Felipe, et al.. (2012). Predicting self-perceived antimuscarinic therapy effectiveness on overactive bladder symptoms using the Overactive Bladder 8-Question Awareness Tool. International Urogynecology Journal. 24(4). 573–581. 4 indexed citations
17.
Arlandis, Salvador, et al.. (2012). Quality of Life in Patients with Overactive Bladder. Clinical Drug Investigation. 32(8). 523–532. 24 indexed citations
18.
19.
20.
Castro‐Díaz, David, et al.. (2011). Evaluación de los motivos del cambio de tratamiento para la vejiga hiperactiva. Actas Urológicas Españolas. 35(2). 73–79. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alexander Gomelsky Breakdown of academic impact, for papers by Karen Irvine‐Bird Breakdown of academic impact, for papers by Danny Lovatsis Breakdown of academic impact, for papers by David Collas Breakdown of academic impact, for papers by Yik N. Lim Breakdown of academic impact, for papers by Hege Hølmo Johannessen Breakdown of academic impact, for papers by Lisa A. Trusler Breakdown of academic impact, for papers by Lauren N. Wood Breakdown of academic impact, for papers by Ayhan Karabulut Breakdown of academic impact, for papers by Marc E. A. Spaanderman
Rankless by CCL
2026